Enter your username/e-mail and your new password will be send to you.

Project

EUNCL

Title European Nanomedicine Characterization Laboratory
Grant Agreement Number 654190
Funding Programmes H2020
Budget Total: €5,627,303.50, EC Contribution: €4,995,181.00
Dates 01/05/2015 - 30/04/2019
Project URL http://www.euncl.eu/
Scientific Domain Biological and Medical Sciences
Type Of Project RIA
Abstract In order to accelerate the development of the nanomedicine business in Europe, EU-NCL interconnects 8 European and 1 American key reference facilities with a proven expertise in physical, chemical, in vitro and in vivo biological characterisation of nanoparticles for medical applications. The objective is to reach a level of international excellence in nanomedicine characterization for all medical indication, and make it accessible to all organisations developing candidate nanomedicines prior to their submission to the regulatory agencies in order to get the approval for clinical trials and later the marketing authorization. EU-NCL is partnered with the sole international reference facility namely the Nanotechnology Characterisation Lab of the USA to get a faster international harmonization of analytical protocols. EU-NCL is closely connected to national medicine agencies and to the European Medicine Agency in order to permanently adapt its analytical services to the need and requests of the regulators. EU-NCL is designed, organized and operated according to the highest EU regulatory and quality standards in order to provide a full analytical cascade of 42 assays. Within EU-NCL, 6 analytical facilities will offer a Trans National Access to their existing analytical services but they will also develop new or improved analytical assays under the Joint Research Activities in order to keep EU-NCL at the cutting edge of the nanomedicine characterisation. A complementary set of networking activities will make EU-NCL able to deliver to the European academic or industrial scientists the best analytical services they dramatically require for accelerating the industrial development of their candidate nanomedicines. An exploitation and business plan will be proposed at the end of the project in order to submit a sustainable development plan beyond the initial period of 4 years.
Coordinator
(Organisation name and Country, EC contribution to budget) 		COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, France, (€944,426.25)
Partners
(Organisation name and Country, EC contribution to budget) 		THE PROVOST, FELLOWS, FOUNDATION SCHOLARS & THE OTHER MEMBERS OF BOARD OF THE COLLEGE OF THE HOLY & UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN, Ireland, (€442,433.75)
EIDGENOESSISCHE MATERIALPRUEFUNGS- UND FORSCHUNGSANSTALT, Switzerland, (€0.00)
STIFTELSEN SINTEF, Norway, (€812,346.25)
JOINT RESEARCH CENTRE- EUROPEAN COMMISSION, European Union, (€827,472.50)
THE UNIVERSITY OF LIVERPOOL, United Kingdom, (€650,716.25)
GESELLSCHAFT FUR BIOANALYTIK MUNSTER EV, Germany, (€866,206.00)
LEIDOS BIOMEDICAL RESEARCH INC, United States, (€348,700.00)
EUROPEAN RESEARCH SERVICES GMBH, Germany, (€102,880.00)